Sunday, November 8, 2026

Revolutionary Radiation-Proof Material Developed by Turkish Scientists

Ozge Guzel

June 8, 2018

Ege Public university in Bornova, Turkey.
ANKARA, Turkey (ViaNews) - A group of doctorate students in the Institute of Nuclear Sciences Department at Ege University developed a clothing material for their medical staff who had been exposed to radiation on a daily basis due to their professions. Professor Fatma Yurt Onaran said to Diken, a Turkish newspaper, that the medical staff working in the radiology and nuclear medicine fields usually had to wear lead composite aprons but these aprons were weighty and disadvantageous. Onaran also explained that these aprons have a short lifespan because of the toxic effects, height, and fragility of lead, the material used in the product. She went on saying, “In this project, my doctorate students and I have focused on the production of a new material that can minimize these disadvantages and we have developed a material made of metal-polymer composites.” Onaran stressed the new material is much lighter and more flexible than the lead aprons, and an even more effective radiation shielding effect. “This new material will be nontoxic, light, environmentally friendly, and convenient. We have already patented our new shielding material and have also prepared a prototype of thyroid protectors”, said Prof. Onaran. Contributors to this project besides Prof Onaran are Alparslan Erol, Isa Pocan, Emre Yanbay, Onur Alp Ersoz, and Fatma Yurt Lambrecht. According to the the Turkish publication, Hurriyet, the rector of the university, Prof. Dr Necdet Budak, emphasized the importance of this new development. “This is a significant development for Turkey as well. Our country is foreign-dependent with regard to the importing of these x-ray and gamma resistant materials. I believe this scientific development will put an end to this dependence. Our universities are full of bright and talented students. We will support our students and academics until we achieve commercial success and improve our economy.”

Categories

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com